HopeStage
Back to all studies
Active Not RecruitingNCT05947383

Up to two psilocybin doses for depression in people with cancer

About this titleRead the official source — NCT05947383

Researchers are comparing Psilocybin and placebo to find out how the approaches affect depression symptoms in adults with depression.

Medication studyAges 18+United States
The study in practice

Understand this study

What is this study about?

Researchers are comparing Psilocybin and placebo to find out how the approaches affect depression symptoms in adults with depression.

Who could participate?

This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.

Listed locations
RockvilleSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: October 23, 2023
Recruitment status
Active Not Recruiting
Enrollment listed in the registry
56
Sponsor
Sunstone Medical
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT05947383
Official title
Show the full official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer

Recruitment & locations

Not recruiting

Rockville

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing Psilocybin and placebo to find out how the approaches affect depression symptoms in adults with depression.

Who is behind this study?

The study sponsor is Sunstone Medical.

Does this study involve medication?

Yes. The study involves medication, including Psilocybin and Placebo.

Who can participate?

This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as active, but no longer recruiting.

Want to explore more studies?

Explore studies